Instalab
logoInstalab

Chromogranin A

Blood Test
Help follow a known neuroendocrine tumor alongside scans, when the tumor releases this protein.
4.9 (2,943 reviews)
Tested by Quest Diagnostics
Physician-reviewed results
Results in under 1 week
How it works
Order from Instalab
No prescription or your own doctor's order needed
Get blood drawn
At home or at 2,000+ patient service centers
Get results
Explained with clear next steps, no medical jargon

Should you take a Chromogranin A test?

This test is most useful if any of these apply to you.

Monitoring a Known Neuroendocrine Tumor
Your tumor has raised this marker before, and repeat levels may add information to your scans and symptoms.
Following Up After Tumor Treatment
Your marker was raised before treatment, and you're using it as one part of follow-up for possible recurrence.

About Chromogranin A

If you're being followed for a known neuroendocrine tumor, chromogranin A may add information to your scans and symptoms, particularly if it was raised when the tumor was diagnosed. Its usefulness varies. Some tumors release little of the protein, while heartburn medication, kidney disease, and other conditions can raise it without a tumor.

What This Protein Is

Chromogranin A, usually shortened to CgA, is stored inside small sacs in neuroendocrine cells and released alongside their hormones. Neuroendocrine cells make hormones in response to nerve and chemical signals. They're found in the gut, pancreas, lungs, adrenal glands, and other tissues.

Your blood concentration depends on how much these cells release and how quickly your body clears the protein and its fragments. A tumor can increase that release, but the result isn't a direct measurement of tumor size or the total amount of neuroendocrine tissue.

What the LC-MS Result Measures

This test measures CgA in serum obtained from a blood draw. The laboratory breaks the protein into smaller pieces, separates them, and measures a characteristic piece with an instrument that identifies molecules by their mass. This method is called LC-MS/MS. That signal is used to calculate the protein concentration.

Many other CgA tests use antibodies. Different methods recognize or quantify different parts of the protein and can produce substantially different results. LC-MS avoids dependence on antibody binding, but results from different methods aren't interchangeable.

Much of the clinical evidence about CgA comes from serum or plasma antibody assays. Those studies support the biological associations described below, but their numerical results and monitoring rules cannot be transferred directly to serum LC-MS. The LC-MS validation study established laboratory performance; it didn't establish how accurately this method detects tumor progression.

Neuroendocrine Tumors

Neuroendocrine tumors are often called NETs. They can arise in the small intestine, pancreas, lungs, stomach, rectum, and other sites. Many grow slowly, though their behavior varies. Some release hormones that cause flushing, diarrhea, wheezing, or other symptoms. Others cause no hormone-related symptoms.

CgA can be raised in tumors that cause hormone-related symptoms and in those that don't. Studies using antibody assays have generally found higher concentrations with more extensive disease, including spread to the liver, but the relationship varies by tumor type. A result within the laboratory's range cannot rule out a NET, and an elevated result cannot establish the diagnosis.

Other tumors can also release CgA, including pheochromocytomas, medullary thyroid cancers, some pituitary tumors, and some cancers with neuroendocrine features. This broad distribution limits its ability to identify where a tumor started. Tests for the particular hormones a tumor releases often provide more specific information.

What Monitoring Can Add

CgA is sometimes followed when a known NET previously produced an elevated result. Studies using antibody assays have found that changes can accompany changes in disease activity, and occasionally precede visible recurrence. But early detection of recurrence is unreliable, and it hasn't been established that acting on CgA changes alone improves outcomes.

A prospective study using a serum antibody assay found that its predefined rise identified only about a third of follow-up visits where scans showed progression. This supports treating CgA as additional information alongside imaging. That performance estimate applies to the antibody assay studied, rather than establishing the accuracy of this LC-MS test.

Current expert guidance advises against routinely using CgA to choose or change treatment for advanced gastrointestinal and pancreatic neuroendocrine tumors. Treatment decisions depend on the tumor's location, growth, tissue findings, symptoms, and imaging.

When Results Can Be Misleading

  • Acid-suppressing medication: Proton pump inhibitors such as omeprazole and pantoprazole can cause a substantial biological rise in CgA. Lower stomach acid increases gastrin, which stimulates hormone-producing cells in the stomach lining. Some H2 blockers can also affect the result, usually less strongly. These changes can occur without a tumor.
  • Atrophic gastritis: Damage to the stomach lining can reduce acid production and increase gastrin and CgA. Serum studies using antibody assays have found elevations in autoimmune gastritis even without a gastric NET.
  • Kidney function: The kidneys help clear CgA and its fragments. Reduced kidney function can raise the concentration and obscure the contribution from a tumor. Changing kidney function can also distort a trend.
  • Other illnesses: Studies using antibody assays have reported higher circulating CgA in heart failure, liver cirrhosis, and inflammatory bowel disease. These conditions need to be considered before attributing an increase to cancer.
  • Sample handling with LC-MS: Refrigerating serum can falsely increase the result with this assay. Severe damage to red blood cells in the sample can suppress the analytical signal, and such samples are rejected. Correct collection and processing matter even when the same laboratory is used.

Tracking Your Trend

A trend is most informative when previous results have agreed with the behavior of your particular tumor. A persistent rise deserves review, but medication changes, kidney function, sample handling, and a switch in assay can all produce a misleading pattern. Stable or falling CgA can coexist with tumor progression.

A pretreatment value helps put later results in context. If that value wasn't collected, subsequent measurements can still establish a comparison point. The absence of an earlier result doesn't make every later result useless.

What Moves This Biomarker

Evidence-backed interventions that affect your Chromogranin A level

↓ Decrease
Surgical removal of a CgA-secreting neuroendocrine tumor or its liver metastases
Removing secreting tumor tissue can produce a large fall in CgA. Small surgical series measured serum CgA using earlier methods and do not provide an expected reduction for this LC-MS assay. A fall alone doesn't confirm that all tumor tissue has been removed.
ProcedureStrong Evidence
↓ Decrease
Lanreotide treatment for selected advanced neuroendocrine tumors
In the randomized CLARINET trial, lanreotide lowered plasma CgA measured by an antibody assay and delayed tumor progression. It also suppresses secretion, so a lower concentration doesn't necessarily mean the tumor has shrunk. The trial did not measure serum CgA by LC-MS.
MedicationModerate Evidence

Frequently Asked Questions

Chromogranin A Test

$189
FSA/HSA eligible
No Rx needed
HIPAA compliant